Paul Reider
Corporate Officer/Principal bij COHERUS BIOSCIENCES, INC.
Vermogen: 156 865 $ op 30-04-2024
Actieve functies van Paul Reider
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| COHERUS BIOSCIENCES, INC. | Corporate Officer/Principal | 01-01-2021 | - |
| TETRAPHASE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Loopbaan van Paul Reider
Eerdere bekende functies van Paul Reider
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Verkoop & Marketing | 01-01-2019 | 01-01-2021 |
| Ipsen Biopharmaceuticals Canada, Inc. | Corporate Officer/Principal | - | - |
Opleiding van Paul Reider
| Bowling Green State University | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 5 |
| Canada | 2 |
Operationeel
| Corporate Officer/Principal | 3 |
| Sales & Marketing | 1 |
| Masters Business Admin | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| COHERUS BIOSCIENCES, INC. | Health Technology |
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
| Ipsen Biopharmaceuticals Canada, Inc. |
- Beurs
- Insiders
- Paul Reider
- Ervaring